News | December 20, 2021
Moderna says Covid-19 booster dose works against Omicron in lab study
Authorized booster increases Omicron neutralizing antibody levels approximately 37-fold
Authorized booster increases Omicron neutralizing antibody levels approximately 37-fold
The deepCDR engine combines deep sequencing and deep learning methods with a proprietary mammalian display process to select from a wide range of antibodies and rapidly identify candidates with the highest possible affinity and developability profiles
Syngene will also build and operate a new dedicated drug development laboratory to accelerate the advancement of Amgen R&D projects
_256_384.jpg)
In Japan, breast cancer is the most common cancer in women, with approximately 92,000 cases of breast cancer diagnosed in 2020
The company will manufacture a cancer immunotherapy product from 2022
Ichnos will receive an upfront payment of Euro 20.8 million as well as additional development and commercial milestone payments and tiered royalties based upon future global sales
Phase 1 study of quadrivalent flu vaccine (mRNA-1010) successfully boosted titers against all four strains in older and younger adults, even at lowest dose; no significant safety concerns were observed
According to the companies’ preliminary data, a third dose provides a similar level of neutralizing antibodies to Omicron as is observed after two doses against wild-type and other variants that emerged before Omicron
Data builds on promising signal published last week, underscoring the importance of sotrovimab for early treatment of COVID-19
The Institute of Pulmonology Medical Research & Development organised a symposium on early management of Covid-19
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
